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2214-0247/Copyright ª 2014, TaiwanAbstract Epidermal growth factor receptor (EGFR) is a member of the transmembrane re-
ceptor tyrosine kinase family. In normal and malignant cells, activation of the EGFR cascade
is involved in the regulation of various cellular activities. The objective of this study was to
identify and assess associations of positive EGFR expression and K-RAS mutations with various
clinicopathological parameters and survival of colorectal carcinoma patients. EGFR of colo-
rectal cancer (CRC) tissue specimens was subjected to immunohistochemical analysis, poly-
merase chain reaction, and DNA sequencing. Immunohistochemical staining was performed
using monoclonal antibodies against EGFR antigens and examination of mutations was per-
formed to detect mutations in codons 12 and 13 of the K-RAS. Statistical analysis was per-
formed using SPSS version 16.0. The results of this study showed that of the 40 study
participants, 62.5% (25/40) showed positive EGFR overexpression. Of the patients showing pos-
itive EGFR expressions, 52% had mutations in the K-RAS. Mutations were spread in codon 12
(64.3%) and codon 13 (35.7%) and there was one sample with mutations in codons 12 and 13t of Digestive Surgery, Wahidin Sudirohusodo Hospital Faculty of Medicine, Hasanuddin University,
o.com (W. Warsinggih).
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2 W. Warsinggih et al.at the same time. A statistically significant association was found between the presence of
metastasis and EGFR overexpression and survival of CRC patients. In addition, a significant as-
sociation was found between K-RAS mutations and metastasis and survival of CRC patients. In
conclusion, EGFR overexpression and K-RAS mutations were found in CRC patients. Both fac-
tors are known to be associated with poor prognosis of cancer patients in terms of patient sur-
vival. Early detection of K-RAS mutations in CRC patients is a crucial component in the
determination of the type of therapy and treatment for the patient.
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.Introduction
One of the most promising molecular targets is the
epidermal growth factor receptor (EGFR), often referred to
as HER1. EGFR is a member of the transmembrane receptor
tyrosine kinase family. In normal and malignant cells,
activation of EGFR receptor cascade is involved in the
regulation of various cellular activities, including cell
growth, differentiation, and proliferation. The EGFR
signaling pathway can also increase cancer cell trans-
formation, angiogenesis, and metastasis.1 These effects are
mediated by multiple signaling mechanisms, such as the
signaling pathways of mitogen-activated protein kinase
(MAPK) and phosphatidylinositol-3 kinase.2 The high
expression of EGFR is known to be associated with exac-
erbation of tumor stage, treatment resistance3,4 and, in
some types of tumors, poor prognosis.5,6
K-RAS is a signal transduction downstream of receptor
tyrosine kinases, one of which is EGFR. EGFR signaling
pathways are activated when it binds to its ligands, such
as the transforming growth factor-a and EGF. Upon EGFR
stimulation, K-RAS proteins are immediately activated,
leading to a strictly regulated activity of RAF/mitogen-
activated protein kinase (MAPK)/extracellular-signal
regulated kinase (ERK) signaling pathways. Mutations in
the K-RAS gene lead to altered activity of the protein,
which occur in approximately 30e50% of colorectal car-
cinoma (CRC) patients.7 K-RAS protein, also called p21, is
a member of the Ras superfamily of proteins, is located
on human chromosome 12 and encoded by 189 amino
acids, and contains four coding exons and a 50-noncoding
exon.8
In normal physiological conditions, the EGFR upstream
signals such as EGF can activate K-RAS through the ex-
change of guanosine diphosphate (GDP) for guanosine
triphosphate (GTP). This process occurs only temporarily
due to the presence of the GTPase-activating proteins
(GAP) that will hydrolyze GTP to GDP again. However, this
process will change when K-RAS undergoes mutation,
resulting in abnormal activity of the GTPase intrinsic to K-
RAS, and preventing GAP from hydrolyzing GTP in K-RAS.
This leads the K-RAS proteins to accumulate in a GTP-bound
form and become permanently activated. Mutant K-RAS
leads to K-RAS being continuously activated and activates a
variety of intracellular signaling pathways.9,10 Thus, K-RAS
mutations play an important role in human tumorigenic
processes, commonly occurring in patients with pancreatic,
thyroid, lung, and colorectal cancer.Association of EGFR and K-RAS mutations with prognosis
of cancer patients remains controversial. In Indonesia,
there is still a dearth of information on the association of
EGFR expression and K-RAS mutations with clinical out-
comes and survival of CRC patients. Thus, the purpose of
the present study was to determine the association of EGFR
expression and metastasis with the survival of CRC patients
and to analyze association of EGFR expression and K-RAS
mutations with the survival of cancer patients.
Materials and methods
Patients
The participants were 40 CRC patients treated at the
Department of Surgery of Hasanuddin University’s Faculty
of Medicine/Dr. Wahidin Sudirohusodo Hospital and
networking teaching hospitals in Makassar, Indonesia. The
study was conducted from June 2010 to October 2010. Pa-
tient data collected included: identity (name, age, and
sex); location of tumor; metastases; histopathological
diagnosis; and grading of differentiation, recurrence, and
mortality observed for 1 year after sampling. Paraffin-
embedded CRC tissue blocks were collected for further
analysis. The study was approved by the biomedical
research ethics committee at the Faculty of Medicine of
Hasanuddin University with Registration Number
UH.10110207 of 2010 and recommendation of ethical
approval number 0018/H 04845.31/0036/Komotik/2011.
Hematoxylineeosin staining
Histopathological profiles of CRC tissue were analyzed using
hematoxylineeosin staining. Sample deparaffinization was
performed using xylene and dehydration using alcohol.
Slides were then washed with running water for 15 minutes
and soaked in hematoxylin solution for 10e15 minutes.
Slides were then washed with running water for 15 minutes
and dipped in 1% acid alcohol. Subsequently, slides were
dipped in liquid ammonia and stained with 1% eosin for
10e15 minutes. Results of staining were observed under a
microscope at 400 magnification.
Immunohistochemical analysis of EGFR expression
Immunohistochemical staining was conducted to observe
expression of EGFR proteins in CRC tissues. Slides were
Associations of positive EGFR expression 3deparaffinized using xylene and dehydrated using an
alcohol series. Subsequently, slides were soaked in citrate
buffer at a pH of 6 and heated at 95C. After blocking with
3% H2O2 in methanol (endogenous blocking), an Ab-5, clone
H11, monoclonal antibody (Lab Vision Corp., Freemont, CA,
USA) in 0.2% BSA was added. Counterstaining was per-
formed using Mayer’s hematoxylin for 5e10 minutes at
room temperature. Slides were then Entellan-mounted and
observed under a microscope at 400 magnification to
count cells expressing EGFR. Positive cells were calculated
per 100 cells on at least 10 fields of each slide. EGFR
expression was considered positive if it was found in > 1% of
tumor cells in partially or completely stained membranes.
It was considered negative if  1% of neoplastic cells
showed the specific staining.
DNA extraction of CRC tissues
DNA was extracted from 5e10 sections of 20 mm-thick
formalin-fixed, paraffin-embedded cancer tissues using
QIAamp FFPE Tissue kit (Qiagen, Valencia, CA, USA) ac-
cording to manufacturer’s instructions.
K-RAS amplification
Polymerase chain reaction (PCR) was performed using ABI
9700 Thermal Cycler (Applied Biosystems, Foster City, CA,
USA) with a volume of 50 mL containing 20mM Tris-HCl pH
8.4, 50mM KCl, 1.5mM MgCl, 200mM dNTP, 400nM sense and
antisense primers, 2 units of Platinum Taq DNA Polymerase
(Invitrogen, Carlsbad, CA, USA), and 5 mL extracted DNA.
Primer pairs for the first PCR reaction were 50-TCAT-
TATTTTTATTATAAGGCCTGCTGAA-30 and 50-ATATGCA-
TATTAAAACAAGATTTACC-30 with a targeted product size of
189 bp. Primer pairs for the second reaction were 50-
GCCTGCTGAAAATGACTGAAT-30 and 50-CAAAGACTGGTCCTG
CACCAGTA-30 with a product size of 170 bp. PCR process
was performed for 35 cycles with predenaturation and
denaturation at 94C, annealing at 53C, and elongation
and final elongation at 72C. The second reaction used the
same conditions, except for annealing at 55C and for
template that used 5 mL of PCR product of the first reac-
tion. Successful PCR was confirmed by agarose gel elec-
trophoresis at 80 V for 30 minutes. Positive results were
marked by 189-bp DNA band from the first PCR reaction or
170-bp DNA band from the second PCR reaction.
DNA fragment purification
Purification of DNA fragments from PCR reactions was
performed using QIAQuick kit (Qiagen). Purification was
carried out by gel cut purification for PCR products con-
taining nonspecific bands.
DNA sequencing
Sequencing began with sequencing cycle on 15 mL 1 buffer
solution containing 1 unit of BigDye terminator version 3.1
(Applied Biosystems), 0.2mM primers, and 2e5 mL of DNA
fragments of purified PCR products. The sequencing cycle
reaction was run at denaturation temperature of 96C for10 seconds, annealing temperature of 50C for 5 seconds,
and elongation temperature of 60C for 4 minutes, for 25
cycles. Predenaturation was carried out in the beginning of
the reaction at 96C for 3 minutes. Sequencing was per-
formed using capillary-based ABI 3130xl DNA sequencer
(Applied Biosystems). The dried sample was dissolved by
adding 11 mL of Hidi solution, and then put in a 96-well
plate. DNA sequencing electropherogram was downloaded
for editing and analysis. Editing was done using BioEdit
version 7.0.5 (Ibis Bioscience, Carlsbad, CA, USA) and
FinchTV version 1.4.0 (Geospiza, Inc. Seattle, WA, USA). In
order to determine the occurrence of mutations edited
sequencing results were aligned with K-RAS sequences
downloaded from GenBank with Access Number NC_000012:
c25295121-25249447.
Statistical analysis
Data were processed and then analyzed descriptively using
SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA)
in order to determine the association between EGFR over-
expression and K-RAS mutations with metastasis/recur-
rence and patient mortality. Then, data were statistically
tested using Pearson’s Chi-square test. Overall survival
rates were calculated by the KaplaneMeier method, and
the differences in survival rates were analyzed by the log-
rank test. Significance was determined at p < 0.05. If
data were unqualified for Pearson’s Chi-square test,
Fisher’s exact test was used.
Results
Patients and clinical characteristics
Table 1 summarizes the overall patient and clinical char-
acteristics. Participants of this study consisted of 57.5%
men and 42.5% women aged 15e71 years (mean  standard
deviation Z 52.82  13.57 years). Age was < 40 years in
22.5% and  40 years in 77.5%. The highest percentage of
the participants (55.0%) was of the Bugis ethnic group,
followed by Makassar (27.5%), Toraja (12.5%), and Javanese
(5.0%).
Based on CRC sites, 57.5% were found in the rectum,
25.0% in the sigmoid colon, 10.0% in the ascending colon,
5.0% in the transverse colon, and 2.5% in the descending
colon. A histopathologically low grade was found in 55.0% of
patients and a histopathologically high grade in 45.0%.
Immunohistochemical examination of 40 tumor tissue
samples found 62.5% (25/40) of patients with positive EGFR
expression and 37.5% (15/40) with negative EGFR expres-
sion (1% cutoff point).
Association of EGFR overexpression with
histopathological grading of CRC patients
Analysis of the association of EGFR overexpression with
histopathological grading of CRC patients indicated that, of
25 patients with positive EGFR expression, 13 (32.5%)
showed a histopathologically low grade and 12 (30.0%)
showed a high histopathologically grade. In patients with
Table 3 The association between EGFR overexpression
and metastasis incidence.
EGFR
overexpression
Metastasis incidence Total
(n Z 40)Present
(n Z 20)
None
(n Z 20)
Negative 11 4 15
Positive 9 16 25
Table 1 The distribution of patients and clinical
characteristics.
Characteristics Distribution
No. (n Z 40) %
Sex
Male 23 57.5
Female 17 42.5
Age
15e40 y 9 22.5
41e80 y 31 77.5
Race
Bugis 22 55.0
Makassar 11 27.5
Toraja 5 12.5
Javanese 2 5.0
Tumor location
Ascendens colon 4 10.0
Transversum colon 2 5.0
Descendens colon 1 2.5
Sigmoid colon 10 25.0
Rectum 23 57.5
Pathologic diagnosis
Adenocarcinoma 33 82.5
Mucinous adenocarcinoma 7 17.5
Histopathology grading
Low grade 22 55.0
High grade 18 45.0
4 W. Warsinggih et al.negative EGFR overexpression, we found nine (22.5%) with
histopathologically low grade and six (15.0%) patients
showed a high histopathologically grade, as seen in Table 2.
Association of EGFR overexpression with metastasis
of CRC patients
Table 3 shows the association of EGFR overexpression with
metastasis of CRC patients. Of 62.5% (25/40) of positive
samples with EGFR overexpression, 40.0% (16/40) of pa-
tients had metastasis. Of those with negative EGFR over-
expression, 10% (4/40) of patients had metastasis. A
significant association (p Z 0.022) of metastatic incidence
with EGFR overexpression was found.
Survival of CRC patients based on EGFR
overexpression
CRC patients with positive EGFR overexpression had a survival
of 15.4 months and 100.0% for up to 6 months. After 8e10Table 2 The association between EGFR overexpression
and histopathology grading.
EGFR
overexpression
Histopathology grading Total
(n Z 40)Low grade
(n Z 22)
High grade
(n Z 18)
Negative 9 6 15
Positive 13 12 25months, survival declined to 90.0%. After 10e11 months,
survival declined to 86.0%, and subsequently to 76.0% after 17
months. CRC patients with negative EGFR overexpression had
a survival of 17.0months and100.0% for up to17months. After
17 months, survival declined to 76.0% (Fig. 1).
Survival of CRC patients based on EGFR
overexpression and K-RAS gene
CRC patients with positive EGFR expression or CRC patients
with K-RAS mutation had a survival rate of 16.3 months.
CRC patients with positive EGFR overexpression and K-RAS
mutation had a lower survival rate of 14.0 months. CRC
patients with negative EGFR overexpression and K-RAS
normal had survival rate of 17.0 months.
CRC patients with positive EGFR overexpression or K-RAS
mutation had a 100.0% survival up to 9 months, after which
it declined to 90.0%. CRC patients with positive EGFR
overexpression and K-RAS mutations obtained had a 100.0%
survival up to 6 months, which it dropped to 80.0% after
6e10 months, and dropped again at 11 months to 64.0%
(Fig. 1). CRC patients with negative EGFR overexpression
and normal K-RAS had a 100.0% survival up to 17 months,
after which it declined to 74.0%.
Discussion
Results show that CRC was most often found in the rectum
(57.5%). This differs from previous studies that found that
CRC was most often found in the colon, with rectum as the
second most frequent site of CRC.11,12 EGFR overexpression
and histopathological grading in this study showed no sig-
nificant association (p Z 0.512). This result was supported
by other studies that reported no association of histo-
pathological grading with EGFR overexpression.13 Immuno-
histochemical analysis of EGFR expression in this study
indicated that 62.5% of the samples had positive EGFR
expression.
EGFR protein, often referred to as HER1, is a member of
the transmembrane receptor tyrosine kinase family, in
which cascade activation of this receptor is involved in the
regulation of cell growth, proliferation, and differentia-
tion. The EGFR signaling pathway can also enhance malig-
nant transformation, angiogenesis, and metastasis.1 EGFR
catalyzes the transfer of phosphate molecules from ATP to
active sites of the tyrosine kinase to mediate the signaling
cascade. Upon binding to its ligand, EGFR will undergo
homodimerization and transphosphorylation of several
tyrosine kinase domains to initiate intracellular EGFR
signaling pathways, which, among others, include
Figure 1 The KaplaneMeier survival curve for colorectal carcinoma. (A) The blue line is negative EGFR. The green line is positive
EGFR. (B) The blue line is wild type K-RAS and negative EGFR. The green line is K-RAS mutation or positive EGRF. The brown line is
K-RAS mutation and positive EGFR.
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tion (STAT) proteins, Sarcoma-family kinases (SRC) family
kinase, Protein kinase B (AKT) proteins, and MAPK signaling
pathways. Activation of those various proteins and signaling
pathways will subsequently induce transcription of genes
involved in various cellular processes such as cell division
and self-defense, all of which describe the role of EGFR in
the process of tumor cell growth.14
EGFR overexpression has been reported in 25e82% of
patients with colorectal cancer15; however, its clinical
significance in colorectal cancer remains unclear. A study
conducted in 249 colorectal cancer patients showed an
association of EGFR overexpression with tumor grade (low
differentiation; pZ 0.014),16 but another study showed no
such association.17 In addition, there were other studies
that found an association of EGFR overexpression with
decreased patient survival rate,13,17 but other studies
found no such association.15
The present study found a significant association
(p Z 0.050) of EGFR overexpression with patients’ clinical
outcome of metastatic process. Other studies have shown
that 50% of CRC patients had metastases that contributed to
the high rate of mortality in CRC patients. EGFR expression
was reported to be associated with increased aggressiveness
of the disease,18 increased risk of metastasis,19 and a more
severe stage of the tumor.20 Several studies have shown that
metastatic lesions were present in the genomic differences
of the primary tumor.21,22 A previous study showed that a
higher EGFR reactivity is found in lymph nodes and metas-
tases compared to primary tumors.13 In addition, EGFR
reactivity in the innermost region of the primary tumor cor-
relatesmost stronglywith EGFR reactivity in the lymphnodes
and metastatic liver. Patients with positive EGFR over-
expression showed a poorer prognosis compared with those
with negative EGFR overexpression, and showed a significant
correlationwithadvanced stages of cancer. A study inTaiwan
concluded that EGFR expression has a prognostic value only
for patients with metachronous, and not synchronous,
metastasis.23EGFR-positive patients with mutated K-RAS gene had a
significantly lower rate of survival than those with no K-RAS
mutations. PCR analysis indicated that 52% of EGFR-positive
patients had K-RAS mutation. All patients with K-RAS mu-
tation were known to have metastatic conditions. Muta-
tions in the K-RAS are thought to cause a less properly
regulated increase in EGFR signaling pathways. Data of the
present study showed that K-RAS mutations could be used
as a marker of aggressive tumor phenotype, as shown by the
association of K-RAS mutation with metastatic cancer cells.
However, the prognostic significance of K-RAS mutation
remains controversial. Incidence of mutations in K-RAS in
several studies was related to the shortening of patient
survival.24e26 However, other studies found no correlation
of K-RAS mutation with patients’ survival rate.27e29 A pre-
vious study showed an increase in the mortality rate of
colon cancer patients with a K-RAS mutation in codon 13
(G/ A), but not K-RAS mutations in general.24
In addition, K-RAS mutations do not have a prognostic
value in patients with metachronous or synchronous
metastasis of CRC.30 This raises a speculation that the
prognosis of cancer patients is associated with specific
mutations of K-RAS and may be related to the race and
environmental factors among patients.
There are three RAS in the human genome, K-RAS, HRas,
and NRas. Mutations of the K-RAS have detected in 35e45%
of CRC patients,30e33 whereas NRas and HRas mutations
were only found in 1e3% of patients with CRC. In the pre-
sent study, 64.3% of K-RAS mutations were distributed in
codon 12 and 35.7% in codon 13, and there was one patient
with mutations in codons 12 and 13. These results are
consistent with previous studies,34 which showed that mu-
tations of K-RAS mostly occurred in codon 12 (77%) and
codon 13 (20%) in exon 2 of the K-RAS. A somatic missense
mutation in codon 12 of the K-RAS lead to substitution of a
single amino acid (Gly/ Val), which is the most common
abnormality found in CRC.
K-RAS encodes GTPase protein that plays a role in the
EGFR-induced downstream cell signaling; thus, this protein
6 W. Warsinggih et al.participates in the highly important activation of oncogenic
signaling pathways. RAS protein is a key element of the
intracellular RAS-MAPK signaling pathway, which leads to
the activation of several other signaling pathways that
control mechanisms of gene transcription, cell prolifera-
tion, apoptosis, angiogenesis, invasion, and migration.35
RAS proteins that play a role in the process of signal
transduction are normally present in the form of active
(RAS-GTP) and inactive (RAS-GDP) conformations. RAS
proteins are activated by guanine nucleotide exchange
factor and inactivated when RAS-GTP is hydrolyzed to RAS-
GDP by GAPs. In normal cells, guanine nucleotide exchange
factor and GAP activity are strictly regulated. Mutations in
K-RAS are capable of leading to a decreased intrinsic
GTPase activity of RAS proteins so that the proteins
become resistant to GAPs. This leads the mutated RAS
proteins to be permanently in the active state (RAS-GTP)
and continuously activates signaling pathways, despite the
lack of induction of cell surface receptors.36e38 Activation
of mutations is thought to be capable of inducing oncogenic
transformation and nonsensitivity to anti-EGFR antibody
therapy, leading to EGFR-independent activation of
phosphatidylinositol-3 kinase/AKT and MAPK signaling
pathways.
In conclusion, EGFR overexpression and K-RAS mutations
were found in CRC patients. Both factors are known to be
associated with poor prognosis of cancer patients in terms
of patient survival. Early detection of K-RAS mutations in
CRC patients is thus a crucial component in the
determination of the type of therapy and treatment for the
patient.Conflicts of interest
All contributing authors declare no conflicts of interest.References
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